*Sandhyarani Guggilla, Iran Gangarapu, Ammavenu and Sarangapani M. 


Introduction: Uterine fibroids, also called fibroid tumors, fibromyomas, myofibroma, leiomyofibroma, fibroleiomyoma, myoma, fibroma and leiomyoma, are benign tumors that develop in uterus. This is the most common tumor of the uterus and female pelvis.[1] The incidence is generally cited as 20–25 percent, but has been shown to be as high as 70–80 percent in studies using histologic and sonographic examinations. Majority of fibroids are asymptomatic; however, when symptomatic, patients present with menstrual disturbances, infertility, lump abdomen or pressure effects.[2] Management of fibroids can be surgical or medical. Among the surgical options, hysterectomy is viewed as the definitive management of symptomatic uterine fibroids. Myomectomy is an alternative for patients who desire childbearing, young patients, and for those who prefer to retain the uterus. Medical management may be given to minimize symptoms and signs, and for patients where surgery is contraindicated. Drugs available are antifibrinolytic-tranexamic acid, danazol, GnRH analogs, progestogens and the antiprogesterone Ulipristal Acetate. Ulipristal Acetate, an antiprogesterone was approved by FDA on September 28, 2000, with the trade name ‗Mifegyne‘ as an abortifacient. The immune reactivity of progesterone receptors in the myoma and myometrial tissue was decreased significantly by this drug, suggesting the regression of these tumors may be obtained through a direct antiprogesterone effect. Varying dosage regimens have been suggested for treatment of fibroids though consensus is for a dose between 5 to 10 mg daily. Higher doses have not shown any increase in the beneficial effect while the side effects have been found to increase.[3] We studied the effect of Ulipristal Acetate given once a week on uterine fibroids for 6 months. The available literature predominantly has studied effects of 3 months exposure with this drug, but in this study, we decided to study the effects of this drug when used for 6 months.

Keywords: Uterine fibroids, also direct antiprogesterone effect.

[Full Text Article]


Forgot Password  |  Register


Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Tangudu Nagabhusana Rao

Download Article : Click here

News & Updation


    FEBRUARY 2019 Issue has been successfully launched on 1 February 2019

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 4.382 to 4.918 due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.


UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS


Copyright From

Covering Letter

                        Author Instruction